Clinical Trials Browser

Phase 1 × Maximum Tolerated Dose × Thoracic × Clear all

NCT01647711 2017-01-31

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Phase 1 Completed

35 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung